Drug Database
MV

MV-130 (Bactek / MV130)

✓ Approved

Inmunotek · Cell-based Therapies · Cell-based Therapies

What is MV-130?

MV-130 is a cell-based therapies developed by Inmunotek. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesBactek, MV130
CompanyInmunotek
Drug ClassCell-based Therapies, Vaccine
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, Inmunotek

Therapeutic Indications

MV-130 is developed for 11 unique indications across 4 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsViral upper respiratory tract infection✓ Approved
Infections and infestationsLower respiratory tract infectionPhase III
Infections and infestationsOtitis mediaPhase II
Infections and infestationsPneumoniaPhase II
Infections and infestationsSinusitisPhase II

+6 more indications available with a free account

Sign up free to view all indications →

Related Research Articles

PubMedEuropean journal of heart failure2026-08-30

Time in blood pressure range and cardiovascular outcomes in HFmrEF/HFpEF: a pooled participant-level analysis of four large-scale trials.

Lu Henri H, Claggett Brian L BL, Ostrominski John W JW, Pfeffer Marc A MA et al.

Blood pressure (BP) control is a Class I recommendation for the management of heart failure with preserved ejection fraction (HFpEF); however, evidence supporting systolic BP (SBP) targets remains limited. We investigated associations between BP control and subsequent outcomes in patients with HF with mildly reduced EF (HFmrEF)/HFpEF. We pooled TOPCAT (Americas), PARAGON-HF, DELIVER, and FINEARTS-HF, which tested spironolactone, sacubitril/valsartan, dapagliflozin, and finerenone, respectively, versus placebo or active control in patients with HF and an LVEF >40% (DELIVER), ≥40% (FINEARTS-HF), or ≥45% (TOPCAT-Americas, PARAGON-HF). Daily BPs were estimated by interpolation from standardized office measurements obtained at randomization and prespecified visits. Time in target range (TIR) was the percentage of the first year after randomization during which SBP was 110-<130 mmHg. Continuous associations between TIR and subsequent risk of HF hospitalization or cardiovascular death, its individual components, and all-cause death was assessed using landmark Cox proportional hazards models with linear splines, adjusted for baseline cardiovascular risk factors. Among 17,788 patients (mean age 72±9 years; 47% women; mean baseline SBP 129±15 mmHg), the median TIR was 38% (≈139 days). Randomization to active therapies increased TIR by 2% (95% CI: -2 to 6) with spironolactone, 7% (5 to 9) with sacubitril/valsartan, 2% (0 to 4) with dapagliflozin, and 3% (1 to 5) with finerenone. Higher TIR was associated with lower subsequent risk of the composite outcome (P=0.021), primarily driven by lower HF hospitalization risk (P=0.007); associations with cardiovascular death and all-cause death were not significant. Sensitivity analyses using stricter (120-<130 mmHg) or more liberal ranges (100-<130 and 120-<140 mmHg) yielded qualitatively similar findings. In patients with HFmrEF/HFpEF, BP control during the first year was associated with a lower subsequent risk of HF hospitalization. ClinicalTrials.gov ID NCT00094302 (TOPCAT), NCT01920711 (PARAGON-HF), NCT03619213 (DELIVER), NCT04435626 (FINEARTS-HF).

PMID 42669134
Read full article →
PubMedChemistry, an Asian journal2026-08-30

Effects of Ligand Electronic Environment on Electrocatalytic Proton Reduction by Cobalt Complexes.

L Karthikeyan K, Mathur Shobhit S, Roy Indrajit I, Maji Somnath S

Here we have synthesized two mononuclear cobalt (II) complexes of type [Co(L)(L/)]ClO4, where L = 4-methyl-N,N-bis((1-methyl-1H-benzo[d]imidazol-2-yl)methyl)aniline, L/ = 2,2/ bipyridine (for 1) and 4,4/-dimethyl-2,2/ bipyridine (for 2). The synthesized complexes were characterized by various spectroscopic techniques and the molecular integrity of the complexes was confirmed by the single crystal x-ray diffraction (SCXRD) analysis. The redox properties of the complexes were analyzed by Cyclic Voltammetry (CV). The electrocatalytic proton reduction studies were done using acetic acid as an external proton source in a non-aqueous medium. The overpotential for the electrocatalytic proton reduction was found to be 453 mV for 1 and 470 mV for 2, consistent with increased electron donation to the metal center by the methyl group in 2, which shifts the reduction potential to more negative values and alters the overpotential. The turnover frequencies (TOF) were 217 and 203 s-1 for 1 and 2, respectively. A plausible catalytic mechanism was proposed based on the experimental observations. The post-catalytic analyses confirmed the structural integrity of the catalysts, indicating homogeneous behavior under catalytic conditions. This study aims to contribute to the development of sustainable and efficient hydrogen production technologies, supporting the transition toward a sustainable energy future.

PMID 42668394
Read full article →
PubMedJACC. CardioOncology2026-08-30

Identifying Patients With Prostate Cancer Who Benefit Most From Routine Cardiovascular Specialist Referral.

Cano Garcia Cristina C, Pinthus Jehonathan J, Avezum Alvaro A, Devereaux P J PJ et al.

RADICAL PC-2 (RAndomizeD Intervention for CArdiovascular and Lifestyle Risk Factors in Prostate Cancer Patients) was a pragmatic randomized controlled trial that tested whether routine referral to a cardiologist or an internist for cardiovascular (CV) risk-factor and lifestyle modification improves outcomes in patients with prostate cancer or receiving androgen-deprivation therapy. The intervention group had more favorable outcomes overall, driven by improved cholesterol control, with no differences in rates of CV death, myocardial infarction (MI), stroke, or heart failure (HF). The authors aim to identify patient subgroups more likely to benefit from routine CV care referral. Prespecified subgroup analyses were used to assess whether patients at higher CV risk derived greater benefit from specialist referral, with treatment-effect heterogeneity assessed using interaction tests. The first primary outcome was a hierarchical composite of CV death, MI, stroke, HF, suboptimal cholesterol, and systolic blood pressure (SBP) control, evaluated using the win ratio. The second primary outcome was time to CV death, MI, stroke, or HF. Among 2487 participants, treatment effect differed by baseline total cholesterol ≤4 mmol/L vs >4 mmol/L (interaction P = 0.016), with respective win ratios of 1.21 (95% CI: 0.89-1.64) and 1.75 (95% CI: 1.51-2.03), and by baseline BP status (SBP ≥130 mm Hg or diastolic BP ≥80 mm Hg vs BP <130/80 mm Hg; interaction P = 0.003), with respective subdistribution HRs (sHRs) for CV death, MI, stroke, or HF of 0.86 (95% CI: 0.61-1.21) and 4.85 (95% CI: 1.65-14.26). The interaction for diabetes did not reach statistical significance (interaction P = 0.054) although the intervention effect estimates suggested a potential difference by diabetes status, with sHRs of 0.53 (95% CI: 0.24-1.15) among participants with diabetes and 1.25 (95% CI: 0.88-1.78) among participants without diabetes. The win ratio was higher among participants with total cholesterol >4 mmol/L, and sHRs were numerically lower among those with SBP ≥130 mm Hg or diastolic BP ≥80 mm Hg and diabetes. Uncontrolled modifiable CV risk factors may identify patients with prostate cancer who are more likely to benefit from routine CV care referral.

PMID 42669076
Read full article →
PubMedJAMA internal medicine2026-08-30

Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial.

Leong Darryl P DP, Higano Celestia C, Cano Garcia Cristina C, Fradet Vincent V et al.

Patients with prostate cancer have a high burden of cardiovascular risk factors, often suboptimally controlled, and adverse cardiovascular outcomes. To determine whether the routine referral of patients with prostate cancer to a cardiovascular specialist to implement a systematic risk factor strategy is more likely to reduce adverse cardiovascular outcomes and improve risk factor control than usual care. This randomized clinical trial included patients with prostate cancer from 55 sites in 8 countries between 2015 and 2025. Eligible patients were diagnosed with prostate cancer during the past 12 months; had received treatment with androgen deprivation therapy (ADT) for the first time within the past 6 months; or planned to start ADT in the next month. Patients taking a statin with a systolic blood pressure of 130 mm Hg or lower were ineligible. Data were analyzed from May 25 to August 7, 2026. Patients were allocated in a 1:1 ratio to receive usual care alone or usual care plus routine referral to an internist or cardiologist. The specialists provided a systematic intervention, including a target of systolic blood pressure of 130 mm Hg or lower and a statin medication, irrespective of the patient's cholesterol levels (even if not usual or guideline-driven practice); encourage smoking cessation; and provide guidance on diet and exercise. Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, suboptimal cholesterol (total cholesterol, >155 mg/dL [to convert to mmol/L, multiply by 0.0259]) and suboptimal blood pressure (systolic blood pressure, >130 mm Hg) as evaluated by the win ratio. The analysis included 2487 patients with prostate cancer (mean [SD] age, 68 [8] years). During median (IQR) follow-up of 5.8 (2.7-8.2) years, the win ratio in favor of the intervention was 1.60 (95% CI, 1.42-1.81), mostly attributable to lower cholesterol in the intervention group (mean difference, 12 mg/dL; 95% CI, 9-15 mg/dL) as a consequence of greater protocol-mandated statin use. Mean (SD) close-out systolic blood pressure values were 131.1 (16.9) mm Hg in the intervention group and 132.9 (18.3) mm Hg in the control group. There was no difference in time to cardiovascular death, myocardial infarction, stroke, or heart failure between groups (subdistribution hazard ratio, 1.08; 95% CI, 0.79-1.49). In this randomized clinical trial, routine referral of patients with prostate cancer to a cardiovascular specialist lead to improved outcomes, specifically through better cholesterol control. However, it is uncertain whether this reduced clinical cardiovascular events. ClinicalTrials.gov Identifier: NCT03127631.

PMID 42669035
Read full article →
PubMedACS applied materials & interfaces2026-08-30

Upshifted d-Band Center and Electron Delocalization in High-Entropy MXene Enabling Highly Reversible Anode-Free Sodium Batteries.

Wang Zhe Z, Hu Xianghui X, Hai Pengqi P, Sun Jiajia J et al.

Anode-free sodium metal batteries (AFSMBs) have attracted significant attention owing to their exceptionally high theoretical energy density and low-cost advantages. However, their practical application is severely hindered by uncontrolled sodium dendrite growth and unstable electrode/electrolyte interfaces. Herein, we propose an interface modification strategy based on high-entropy MXene, (Ti1/5V1/5Zr1/5Nb1/5Ta1/5)2CTx (HE-MXene), to regulate the electronic structure of the current collector. It has been demonstrated that the synergistic interactions among multiple transition metal elements in HE-MXene upshift the d-band center and induce electron delocalization, which effectively enhance sodium ion adsorption and promote uniform charge transfer, ultimately facilitating homogeneous sodium deposition and the formation of an inorganic-rich SEI. As a result, the HE-MXene-modified electrode reduces the sodium nucleation overpotential to 6.2 mV. Specifically, the half-cell achieves stable cycling for over 400 h at 0.5 mA cm-2 and 1 mAh cm-2, while the symmetric cell delivers an extended lifespan exceeding 1500 h at 1 mA cm-2 and 1 mAh cm-2. This work elucidates the electronic mechanism by which interfacial modification layers optimize sodium deposition behavior and SEI chemistry at the atomic scale, offering perspectives for the design of high-performance AFSMBs.

PMID 42669415
Read full article →
PubMedCirculation journal : official journal of the Japanese Circulation Society2026-08-30

Estimated Small Dense Low-Density Lipoprotein Cholesterol Is Independently Associated With Arterial Stiffness　- Large Japanese Screening Study.

Shinchi Shuya S, Akasaki Yuichi Y, Tokutake Daisuke D, Kawasoe Shin S et al.

Small dense low-density lipoprotein cholesterol (sdLDL-C) is an established atherogenic marker; however, the association between estimated sdLDL-C (EsdLDL-C) and arterial stiffness remains unclear. We analyzed 23,623 participants (13,518 men, 10,105 women). EsdLDL-C was calculated using the Sampson equation, and arterial stiffness was defined as a brachial-ankle pulse wave velocity (baPWV) ≥1,400 cm/s. After adjustment for cardiovascular risk factors, higher EsdLDL-C levels were significantly associated with arterial stiffness in the overall population and in men, whereas the association in women did not reach statistical significance in the continuous analysis. Nevertheless, the risk of arterial stiffness increased in a stepwise manner across EsdLDL-C quartiles; the highest EsdLDL-C quartile had a significantly higher risk than the lowest in both men (odds ratio [OR] 1.91; 95% confidence interval [CI] 1.59-2.29) and women (OR 1.54; 95% CI 1.22-1.95). In a 4-group analysis, high EsdLDL-C significantly increased risk, regardless of whether estimated low-density lipoprotein cholesterol levels were below or above the median. Stratified analysis by systolic blood pressure (SBP; <120, 120-129, 130-139, and ≥140 mmHg) revealed that the association was significant across all categories in men, but was less consistent in women and was significant only in the strict normotensive group (SBP <120 mmHg). EsdLDL-C calculated from standard lipid parameters is significantly associated with arterial stiffness. This association is robust in men and evident in normotensive women, suggesting that EsdLDL-C is a useful indicator for arteriosclerotic risk assessment.

PMID 42669485
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about MV-130